Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quince Therapeutics, Inc. - Common Stock (NQ:QNCX)

1.168 -0.012 (-1.02%)
Streaming Delayed Price Updated: 10:15 AM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Quince Therapeutics, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
American Minerals (OTC: AMLM) Strategic Acquisition Expands Gold Assets in Western Australia as Metals Spike – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence Economy
News headline image
Stocks Under $0.10: ITRM, AMLM, BFRG, QNCX, ADMQ March Madness Watch
Via AB Newswire
Topics Artificial Intelligence Economy
News headline image
Quince Therapeutics Settles Approximately $16.4 Million of Debt
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
American Lithium Minerals (OTC: AMLM) Highlights Critical Catalyst Advancements, Multi-Commodity Growth and Upside Potential
Via AB Newswire
Topics Artificial Intelligence
News headline image
Micro-Caps Under $1: TOON, PRSO, RENX, QNCX, KIDZ Building Momentum
Via AB Newswire
Topics Economy Intellectual Property
News headline image
Quince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Alternatives
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics to Participate at Investor Events in December 2025
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Announces Positive iDSMB Review for eDSP in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Announces CPT: Pharmacometrics & Systems Pharmacology Publication of eDSP Population Pharmacokinetic Modeling Study
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Presents Data from Patient-Reported Walking Capacity in Children with Ataxia-Telangiectasia at 54th Child Neurology Society Annual Meeting
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics to Host Virtual Investor Day on October 2, 2025
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Selects Option Care Health as Specialty Infusion Therapy Provider for Administration of Lead Asset eDSP
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Completes Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Appoints Leading Immunologist Dr. Hassan Abolhassani to Scientific Advisory Board
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics to Participate at A-T Society’s 2025 A-T Clinical Research Conference
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Announces Closing of Up to $22 Million Private Placement of Securities
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Announces Pricing of Up to $22 Million Private Placement of Securities
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Exceeds 75% Enrollment in Pivotal Phase 3 NEAT Clinical Trial in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics to Present at Citizens Life Sciences Conference
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics to Present at Jones Healthcare and Technology Innovation Conference
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics Provides Business Update and Reports Fiscal Year 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
News headline image
Quince Therapeutics to Host Investor Webinar Today Focused on Addressing the High Unmet Need in Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.